StreetAlpha.app
Home › Stocks › GRFS

Grifols SA (GRFS)

$8.63
▼ −1.15%
LAST CLOSE · NOV 17

Grifols makes medicines derived from human plasma and diagnostic products for hospitals, clinics and laboratories. It last closed at $8.63 on Nov 17, down 1.15% on the day.

AI Auto Pilots
Is GRFS in one of our four AI portfolios? Sign in free to see

Key Stats

Fiscal 2024
Results
Revenue
EUR 7.2B
+9.4% vs a year ago
Net income
EUR 156.9M
+270.8% vs a year ago
Free cash flow
EUR 669.6M
9.3% margin
Gross margin
38.7%
EUR 2.8B gross profit
Balance sheet
Cash & equivalents
EUR 979.8M
At Dec 31
Shareholder equity
EUR 8.6B
ExchangeNasdaq
Financials history
FY2020: EUR 5.3BEUR 5.3BFY2020FY2021: EUR 4.9BEUR 4.9BFY2021FY2022: EUR 6.1BEUR 6.1BFY2022FY2023: EUR 6.6BEUR 6.6BFY2023FY2024: EUR 7.2BEUR 7.2BFY2024

From GRFS's SEC filings, latest 20-F for the period ending Dec 31, 2024 (filed Apr 17). Figures are in EUR. Per share figures are left out because the US listing can represent a different number of shares.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Hold
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Hold
1firm
0 Buy1 Hold0 Sell
Only 1 firm rated GRFS in the past 90 days, not enough for a consensus
Average 12-month target
$9.00
▲ 4.3% upside

Based on 1 analyst who set a price target on GRFS in the past 90 days. The average target is $9.00, with a high of $9.00 and a low of $9.00, compared with the last close of $8.63.

Low $9.00Avg $9.00High $9.00
Blue marker: last close $8.63
Highest target$9.00
Average target$9.00
Lowest target$9.00
Latest rating changes
JP MorganMaintained
Oct 26Hold$9
DateFirmActionRatingPrice target
Oct 26JP MorganMaintainedHold$9
Loading…

Technical Analysis

GRFS · as of the Nov 17 close · updated after every close
Turning up, nearing overbought

The stock is 4% above its 20 day and 10% above its 50 day average. It is 8% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 64), near overbought. The nearest support is the Pivot S1 at $8.57, and the nearest resistance the Pivot at $8.65.

Short trendBullish
Long trendNeutral
MomentumStrong
StretchNear overbought
VolatilityNormal, 2.6%/day
Key levels
$9.7752 week high+13.2%
$8.71Pivot R1+0.9%
$8.71Swing high (Nov 3)+0.9%
$8.65Pivot+0.2%
$8.63Last close
$8.57Pivot S1−0.7%
$8.3320 day average−3.5%
$8.26Swing low (Nov 6)−4.3%
$7.97200 day average−7.6%
$7.7850 day average−9.8%
$7.74100 day average−10.3%
$6.9652 week low−19.4%
Indicators
RSI (14)64.12Strong, overbought above 70Neutral
MACD0.30Above its signal lineBullish
Stochastic78.3Middle of its rangeNeutral
ADX (14)38.1Trending up
Williams %R-29.2Oversold below −80, overbought above −20Neutral
CCI (20)60.6Oversold below −100, overbought above 100Neutral
Rate of change+0.8%Change over 10 sessionsBullish
ATR (14)$0.22Typical daily range, 2.6% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for GRFS

What happened before

See how GRFS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow GRFS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How GRFS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2011.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in GRFS in the last 90 days.

Loading…

See today’s whale options flow across the market →

GRFS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲84 buying vs 70 selling
  • ▼Shares held by funds -2.7%
  • ▼Funds holding -3
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding165168−1.8%
In funds' top 10330.0%
Held by funds–––
New / increased17 / 6717 / 54+18.3%
Reduced / sold out50 / 2067 / 38−33.3%
Put/call ratio0.910.24+284.3%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See GRFS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether GRFS is in one of them and how their past GRFS trades turned out.

GRFS in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered GRFS in an article yet. Here's the latest on the wider market.

GRFS Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Apr 17
Who traded GRFS · since 2019
Latest 4 filings
$1K – $15KTraded Mar 31, 2023Filed Apr 17, 2023
$1K – $15KTraded Feb 27, 2023Filed Mar 20, 2023
$1K – $15KTraded Jun 24, 2019Filed Apr 27, 2020
$100K – $250KTraded Nov 11, 2019Filed Dec 23, 2019
PersonTypeAmountTradedFiledDelay
Dan GoldmanD · NYSell$1K – $15KMar 31, 2023Apr 17, 202317 d
Dan GoldmanD · NYBuy$1K – $15KFeb 27, 2023Mar 20, 202321 d
Donna ShalalaD · FLSell$1K – $15KJun 24, 2019Apr 27, 2020308 d
Greg GianforteR · MTSell$100K – $250KNov 11, 2019Dec 23, 201942 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Grifols SA

Grifols makes medicines derived from human plasma, the liquid part of blood, and sells them to hospitals, clinics and healthcare providers. These therapies treat conditions such as immune deficiencies, hemophilia and emphysema linked to alpha 1 protein deficiency. The company also makes diagnostic tests and instruments for blood banks and clinical laboratories, along with infusion solutions and nutrition products for hospital use. It is based in New York and runs plasma collection centers to supply its manufacturing.

Headquarters
New York, NY